TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18096409

Group type: EXPERIMENTAL
Intervention: 10% sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: sucralose
Number of subjects: 12
Study: 17063170

Group type: EXPERIMENTAL
Intervention: P400 (400 mg phosphate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: P800 (800 mg phosphate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: P1200 (1200 mg phosphate)
Number of subjects: 8
Study: 12622767

Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg b.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 20
Study: 10967376

Group type: EXPERIMENTAL
Intervention: Cleft palate patients with CAD
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cleft palate patients without CAD (control)
Number of subjects: 58
Study: 9082928

Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 19
Study: 8368545

Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2 mg of epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of 0.2 mg of morphine and 0.2 mg of epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Spinal bupivacaine alone
Number of subjects: 90
Study: 3545737

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Amiloride HCl 5 mg + Hydrochlorothiazide 50 mg (AHCZ)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 29309832

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU oral doses at 8 weeks interval)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 31
Study: 26749356

Group type: EXPERIMENTAL
Intervention: Bar chart (print advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Table (print advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Pictograph (print advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Any visual aid (television advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Bar chart (television advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Pictograph (television advertisement)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Table (television advertisement)
Number of subjects: 2504

Group type: COMPARATOR
Intervention: No visual aid (print and television advertisements)
Number of subjects: 2504
Study: 25903215

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 33
Study: 23658114

Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 13
Study: 21041275

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tramadol hydrochloride
Number of subjects: 0
Study: 18708936

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 28
Study: 16861614

Group type: EXPERIMENTAL
Intervention: Lifestyle case management (CM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 147
Study: 14522295

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (Cosopt)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38
Study: 10795763

Group type: EXPERIMENTAL
Intervention: Oral sodium butyrate (4 g/day) plus oral mesalazine (2.4 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral mesalazine plus placebo
Number of subjects: 30
Study: 8633143

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5, 25, and 50 mumol per kilogram of body weight)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5 mumol)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Breath‐hold, T1‐weighted, fast low‐angle shot pulse sequence
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA
Number of subjects: 33
Study: 1571381

Group type: EXPERIMENTAL
Intervention: 0.25 g of cefodizime
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 0.5 g of cefodizime
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 1.0 g of cefodizime
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Cefodizime (all doses)
Number of subjects: 326
Study: 6488703

Group type: EXPERIMENTAL
Intervention: Infusion of calcium (increased plasma calcium concentration by about 0.5 mmol/l)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Discontinuation of calcium infusion after 46 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Infusion of sodium nitroprusside
Number of subjects: 8

Group type: COMPARATOR
Intervention: Infusion of noradrenaline
Number of subjects: 8
Study: 30284097

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure mask (CPAP), oxygen at 6 L/min, 5-15 cm H2O
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple oxygen mask, oxygen at 6 L/min
Number of subjects: 40
Study: 30216648

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 1489

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1489
Study: 27252150

Group type: EXPERIMENTAL
Intervention: Baseline health-related quality of life (HRQoL) assessed using EORTC QLQ-C30 and BN20 brain cancer module
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Final prognostic model based on HRQoL and clinical parameters
Number of subjects: 134
Study: 25204510

Group type: EXPERIMENTAL
Intervention: Novel ultrasound device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional device
Number of subjects: 20
Study: 22080364

Group type: EXPERIMENTAL
Intervention: Cough test
Number of subjects: 92

Group type: COMPARATOR
Intervention: No cough test
Number of subjects: 92
Study: 20181990

Group type: EXPERIMENTAL
Intervention: Golfers
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 23
Study: 17678469

Group type: EXPERIMENTAL
Intervention: ZDV/ddI-containing regimen
Number of subjects: 0
Study: 16084879

Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 2 mg of E2 plus 1 mg of norethisterone acetate (E2/NETA)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 352

Group type: COMPARATOR
Intervention: No menopausal therapy (control)
Number of subjects: 352
Study: 12115339

Group type: EXPERIMENTAL
Intervention: Problem-solving training intervention (two in-person and four telephone sessions over 12 weeks)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Problem-solving training intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 10408487

Group type: EXPERIMENTAL
Intervention: M. vaccae
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 347
Study: 7473832

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of total calories)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Wheat bran (25 g daily)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Combined intervention of low fat and wheat bran
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411
Study: 2258344

Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg per day)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Ampicillin (4 g per day) plus Gentamicin (240 mg per day im)
Number of subjects: 189
Study: 6112329

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31669049

Group type: EXPERIMENTAL
Intervention: 975 mg oral acetaminophen
Number of subjects: 100
Study: 30550890

Group type: EXPERIMENTAL
Intervention: Receiving education on maternal health
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Best friend's use of maternal care
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Head of the household
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Experience of postpartum complications
Number of subjects: 1206
Study: 27437928

Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed Whey Formula (eHWF)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) and Extensively Hydrolyzed Whey Formula (eHWF)
Number of subjects: 65
Study: 26383910

Group type: EXPERIMENTAL
Intervention: BITSEA (intervention condition)
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 2610
Study: 23430981

Group type: EXPERIMENTAL
Intervention: MTRR haplotypes
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Other haplotypes
Number of subjects: 1966
Study: 20661637

Group type: EXPERIMENTAL
Intervention: Brief integrative multiple behavior intervention
Number of subjects: 479

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 479
Study: 20029102

Group type: COMPARATOR
Intervention: Forward (arch) foot position
Number of subjects: 10
Study: 17968020

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (Ixabepilone 40 mg/m² IV on day 1 of a 21-day cycle plus capecitabine 2000 mg/m² orally on days 1-14 of a 21-day cycle)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Capecitabine alone (2500 mg/m² on the same schedule)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 752

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 752
Study: 16045668

Group type: COMPARATOR
Intervention: Axillary approach for brachial plexus block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Infraclavicular approach for brachial plexus block
Number of subjects: 30
Study: 12121393

Group type: EXPERIMENTAL
Intervention: 50% tea tree oil solution
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 25% tea tree oil solution
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Tea tree oil (both concentrations)
Number of subjects: 158
Study: 9893074

Group type: EXPERIMENTAL
Intervention: Voluntary unsupervised aerobic and step training (twice per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 7758402

Group type: EXPERIMENTAL
Intervention: Marihuana cigarettes containing 1.26% delta 9-THC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Marihuana cigarettes containing 2.53% delta 9-THC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All marihuana groups (1.26% and 2.53% delta 9-THC)
Number of subjects: 18
Study: 2185822

Group type: COMPARATOR
Intervention: Mifepristone 0 mg (placebo)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mifepristone (all doses)
Number of subjects: 230
Study: 391754

Group type: EXPERIMENTAL
Intervention: Pindolol, 15 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30848805

Group type: EXPERIMENTAL
Intervention: Low BMI/Low Alcohol
Number of subjects: 91552

Group type: EXPERIMENTAL
Intervention: Low BMI/High Alcohol
Number of subjects: 91552

Group type: EXPERIMENTAL
Intervention: High BMI/Low Alcohol
Number of subjects: 91552

Group type: COMPARATOR
Intervention: High BMI/High Alcohol (reference group)
Number of subjects: 91552
Study: 27977309

Group type: EXPERIMENTAL
Intervention: Coordinated inhalation maneuver
Number of subjects: 32

Group type: COMPARATOR
Intervention: Uncoordinated inhalation maneuver
Number of subjects: 32
Study: 26124485

Group type: EXPERIMENTAL
Intervention: New ointment containing several antioxidants
Number of subjects: 152

Group type: COMPARATOR
Intervention: Urea cream
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: New ointment
Number of subjects: 152
Study: 23728549

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GERD (+) patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: GERD (-) patients
Number of subjects: 64
Study: 21570071

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound surgery (FUS) treatment of uterine fibroids
Number of subjects: 1
Study: 19447262

Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo technique
Number of subjects: 70
Study: 16249194

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Simvastatin (in vitro)
Number of subjects: 55
Study: 14761114

Group type: EXPERIMENTAL
Intervention: Cyclosporin A-treated patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Periodontitis-affected patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 11034245

Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU) 450 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=74)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Oral doxifluridine 900 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=92)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Quality of life scores
Number of subjects: 166
Study: 8769611

Group type: EXPERIMENTAL
Intervention: 100 mg/kg intravenous hyperimmune globulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 0
Study: 1427133

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of Timolol and Acetazolamide
Number of subjects: 18
Study: 6427816

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30796816

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 72
Study: 28619236

Group type: EXPERIMENTAL
Intervention: ISP+FO
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (wheat flour+corn oil)
Number of subjects: 73
Study: 27035272

Group type: EXPERIMENTAL
Intervention: Reduced B vitamins
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 24788589

Group type: EXPERIMENTAL
Intervention: Antenatal yoga
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 59
Study: 22054112

Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Navy beans
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chickpeas
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All pulses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (pasta and sauce)
Number of subjects: 24
Study: 19117641

Group type: EXPERIMENTAL
Intervention: AD cases with neuronal immunoreactivity for epigenetic markers and factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: AD neurons
Number of subjects: 0
Study: 18324902

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate (group A, n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Parecoxib sodium (group B, n = 28)
Number of subjects: 58
Study: 15756185

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 45
Study: 12186348

Group type: EXPERIMENTAL
Intervention: Emdogain + Bio-Oss (BDX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bio-Oss (BDX) alone
Number of subjects: 24
Study: 10489654

Group type: EXPERIMENTAL
Intervention: Psychomotor Activation Programme (PAP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 9173439

Group type: EXPERIMENTAL
Intervention: Phagocytic activity of blood platelets
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Blood platelets count
Number of subjects: 35
Study: 1750018

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (1 mg in 3 ml saline) via System 22 nebuliser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (1 mg in 3 ml saline) via Fisoneb nebuliser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride via Fisoneb nebuliser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 8
Study: 6311242

Group type: EXPERIMENTAL
Intervention: Pectin (12 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lignin (12 g/d)
Number of subjects: 0
Study: 29925775

Group type: EXPERIMENTAL
Intervention: Inulin supplement (10 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 18
Study: 27152906

Group type: EXPERIMENTAL
Intervention: Low status group
Number of subjects: 0

Group type: COMPARATOR
Intervention: High status group
Number of subjects: 0
Study: 24886443

Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in prediabetic subjects with HbA1c > 5.5% (37 mmol/mol)
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in diabetic patients
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in general population
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: HbA1c levels in non-diabetic persons
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: PLA1A2 polymorphism in participants with HbA1c ranging from 5.5% (37 mmol/mol) to 6.5% (48 mmol/mol)
Number of subjects: 4028
Study: 22492372

Group type: EXPERIMENTAL
Intervention: Methionine intake of 3 to 59 mg kg(‐1) d(‐1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Current recommended methionine intake of 28 mg kg(‐1) d(‐1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Infant formulas providing methionine intake of 49-80 mg kg(‐1) d(‐1)
Number of subjects: 33
Study: 20307216

Group type: EXPERIMENTAL
Intervention: LUMIGAN (bimatoprost ophthalmic solution, 0.03%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TRAVATAN (travoprost ophthalmic solution, 0.004%)
Number of subjects: 12
Study: 18508828

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF), 400 microg once daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 16996600

Group type: EXPERIMENTAL
Intervention: PDT followed by approximately 11 mg IVTA
Number of subjects: 61

Group type: COMPARATOR
Intervention: PDT
Number of subjects: 61
Study: 11855904

Group type: EXPERIMENTAL
Intervention: Implicit power motivation, low activity inhibition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Testosterone increases, low activity inhibition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Testosterone increases in winners, low activity inhibition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Participants high in activity inhibition
Number of subjects: 66
Study: 10442963

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.05 mg x kg(‐1))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.1 mg x kg(‐1))
Number of subjects: 120
Study: 8685641

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g, i.v. every 8 h for 2 days)
Number of subjects: 1079

Group type: COMPARATOR
Intervention: No further antibiotics
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Metronidazole (1 g i.v. at induction and 12 h postoperatively)
Number of subjects: 1079
Study: 1971831

Group type: EXPERIMENTAL
Intervention: Estazolam 2 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 229
Study: 549782

Group type: EXPERIMENTAL
Intervention: Tienilic acid (TA) 250-750 mg/die
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 50-150 mg/die
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tienilic acid (TA) 250-1000 mg/die in congestive heart failure patients
Number of subjects: 30
Study: 31581605

Group type: EXPERIMENTAL
Intervention: Agaricus blazei-based extract AndosanTM
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28030882

Group type: EXPERIMENTAL
Intervention: Conventional hydrogel (Omafilcon A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel (comfilcon A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard environment (50% RH, 23°C, 930 mb atmospheric pressure)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adverse environment (5% RH, localized air flow, 23°C, 750 mb atmospheric pressure)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both environments and CL types
Number of subjects: 54
Study: 25542821

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 451
Study: 23568254

Group type: EXPERIMENTAL
Intervention: PEEK cage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 80
Study: 21034680

Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 133

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 133